334 related articles for article (PubMed ID: 27398024)
1. The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation.
Bow EW; Rimoldi JM
Perspect Medicin Chem; 2016; 8():17-39. PubMed ID: 27398024
[TBL] [Abstract][Full Text] [Related]
2. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
3. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
Reggio PH; Wang T; Brown AE; Fleming DN; Seltzman HH; Griffin G; Pertwee RG; Compton DR; Abood ME; Martin BR
J Med Chem; 1997 Sep; 40(20):3312-8. PubMed ID: 9379452
[TBL] [Abstract][Full Text] [Related]
4. Absence of Entourage: Terpenoids Commonly Found in
Santiago M; Sachdev S; Arnold JC; McGregor IS; Connor M
Cannabis Cannabinoid Res; 2019; 4(3):165-176. PubMed ID: 31559333
[No Abstract] [Full Text] [Related]
5. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
7. Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
Durdagi S; Reis H; Papadopoulos MG; Mavromoustakos T
Bioorg Med Chem; 2008 Aug; 16(15):7377-87. PubMed ID: 18595717
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pharmacology of Phytocannabinoids.
Turner SE; Williams CM; Iversen L; Whalley BJ
Prog Chem Org Nat Prod; 2017; 103():61-101. PubMed ID: 28120231
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
[TBL] [Abstract][Full Text] [Related]
12. A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ
Citti C; Linciano P; Russo F; Luongo L; Iannotta M; Maione S; Laganà A; Capriotti AL; Forni F; Vandelli MA; Gigli G; Cannazza G
Sci Rep; 2019 Dec; 9(1):20335. PubMed ID: 31889124
[TBL] [Abstract][Full Text] [Related]
13. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
14. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
Pertwee RG
Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
[TBL] [Abstract][Full Text] [Related]
15. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.
Walsh KB; McKinney AE; Holmes AE
Front Pharmacol; 2021; 12():777804. PubMed ID: 34916950
[TBL] [Abstract][Full Text] [Related]
16. Molecular Targets of the Phytocannabinoids: A Complex Picture.
Morales P; Hurst DP; Reggio PH
Prog Chem Org Nat Prod; 2017; 103():103-131. PubMed ID: 28120232
[TBL] [Abstract][Full Text] [Related]
17. Behavioral effects of cannabinoid agents in animals.
Chaperon F; Thiébot MH
Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
Wilkinson JD; Williamson EM
J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
